Loading…
School Building Enhancement Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 6,490 other HR bills in the 111th — cohort avg 44d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (4)
2010 · fourth_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Legislation affecting the 340B program including H.R. 4213, American Jobs and Closing Tax Loopholes Act Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act Prescription drug advertising; and federal preemption for prescription drugs.
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · fourth_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S.1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Legislation affecting 340B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Federal preemption for prescription drugs; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; and Prescription drug advertising.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · fourth_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · fourth_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; 340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Prescription drug advertising; Federal preemption for prescription drugs; Legislation affecting telemedicine; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · fourth_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; 340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · fourth_quarter · Health Issues
Drug safety including H.R. 579, the Food and Drug Administration Globalization Act; Comparative effectiveness issues; Congressional oversight issues; Legislation concerning PSE; and general health care reform (Patient Protection and Affordable Care Act implementation issues).
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · fourth_quarter · Health Issues
Drug safety including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; and FY 2011 Financial Services and General Government Appropriations bill; Federal preemption for drugs and devices including H.R. 1346/S. 540, Medical Device Safety Act of 2009; Prescription drug advertising; Congressional oversight issues; and General health care reform (Patient Protection and Affordable Care Act).
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · fourth_quarter · Medical/Disease Research/Clinical Labs
HR 579 Food and Drug Administration Globalization Act 510(k) Reform
Client expense: $240,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Legislation affecting the 340B program including H.R. 4213, American Jobs and Closing Tax Loopholes Act Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act Prescription drug advertising; and federal preemption for prescription drugs.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization act ; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Prescription drug advertising; animal health; and Federal preemption for prescription drugs.
Client expense: Not reported · Firm income: $80,000
2010 · third_quarter · Health Issues
Drug safety including H.R. 579, the Food and Drug Administration Globalization Act; Comparative effectiveness issues; Congressional oversight issues; Legislation concerning PSE; and general health care reform (Patient Protection and Affordable Care Act implementation issues).
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Health Issues
Drug safety including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; and FY 2011 Financial Services and General Government Appropriations bill; Federal preemption for drugs and devices including H.R. 1346/S. 540, Medical Device Safety Act of 2009; Prescription drug advertising; Congressional oversight issues; and General health care reform (Patient Protection and Affordable Care Act).
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S.1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Legislation affecting 340B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Federal preemption for prescription drugs; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; and Prescription drug advertising.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: Not reported · Firm income: $120,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; 340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Prescription drug advertising; Federal preemption for prescription drugs; Legislation affecting telemedicine; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: Not reported · Firm income: $70,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; 340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: Not reported · Firm income: $50,000
2010 · third_quarter · Medical/Disease Research/Clinical Labs
HR 579 Food and Drug Administration Globalization Act 2009 510(k) Reform
Client expense: $210,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2010 · second_quarter · Health Issues
Drug safety including H.R. 579, the Food and Drug Administration Globalization Act; Comparative effectiveness issues; Congressional oversight issues; and Legislation concerning PSE.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · second_quarter · Health Issues
Drug safety including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; Federal preemption for drugs and devices including H.R. 1346/S. 540, Medical Device Safety Act of 2009; Prescription drug advertising; and Congressional oversight issues.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · second_quarter · Medical/Disease Research/Clinical Labs
H.R. 579 Food and Drug Administration Globalization Act 2009 510(k) Reform
Client expense: $250,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2010 · second_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S.1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Legislation affecting 340B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Federal preemption for prescription drugs; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; and Prescription drug advertising.
Client expense: Not reported · Firm income: $50,000
2010 · second_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · second_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; 340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; Prescription drug advertising; Federal preemption for prescription drugs; Legislation affecting telemedicine; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: Not reported · Firm income: $40,000
2010 · second_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; 340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: Not reported · Firm income: $50,000
2010 · second_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization act ; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Senator Kennedy cancer legislation; Prescription drug advertising; and Federal preemption for prescription drugs.
Client expense: Not reported · Firm income: $80,000
2010 · second_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Legislation affecting the 340B program including H.R. 4213, American Jobs and Closing Tax Loopholes Act Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act Prescription drug advertising; and federal preemption for prescription drugs.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · first_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; H.R. 3590, Patient Protection and Affordable Care Act. Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Comparative effectiveness including S. 1213, Patient-Centered Outcomes Research Act of 2009; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act Health care reform including H.R. 3200, America's Affordable Health Choices Act; S. , Affordable Health Choices Act; and S. , America's Healthy Future Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Prescription drug advertising; Federal preemption for prescription drugs.
Client expense: Not reported · Firm income: $40,000
2010 · first_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S.1232, Pharmaceutical Market Access and Drug Safety Act of 2009; H.R. 3590, the Patient Protection and Affordable Care Act. Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Physician payment disclosure including S. 301, Physician Payment Sunshine Act of 2009; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Comparative effectivess including S. 1213, Patient-Centered Outcomes Research Act of 2009; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Health care reform; including H.R. 3200, America's Affordable Health Choices Act; S.___, Affordable Health Choices Act; and S.___ , America's Healthy Future Act; H.R. 3962, Affordable Health Care for America Act; and H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Prescription drug advertising; and Federal preemption for prescription drugs.
2010 · first_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; H.R. 3590, Patient Protection and Affordable Care Act. Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Physician payment disclosure including S. 301, Physician Payments Sunshine Act of 2009; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Comparative effectiveness including S.1213, Patient-Centered Outcomes Research Act of 2009; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Health care reform including H.R. 3200, America's Affordable Health Choices Act; S___, Affordable Health Choices Act; and S. ___, America's Healthy Future Act; H.R. 3962, Affordable Health Care for America Act; and H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
2010 · first_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; H.R. 3590, Patient Protection and Affordable Care Act. Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Physician payment disclosure including S. 301, Physician Payments Sunshine Act of 2009; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Comparative effectiveness including S. 1259, Preserving Access to Targeted, Individualized, and Effective New Treatments and Services Act of 2009; S. 1213, Patient-Centered Outcomes Research Act of 2009; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Health care reform including H.R. 3200, America's Affordable Health Choices Act; S.___, Affordable Health Choices Act; and S.___, America's Healthy Future Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Prescription drug advertising; Federal preemption for prescription drugs; Legislation affecting telemedicine including H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
2010 · first_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; H.R. 3590, Patient Protection and Affordable Care Act. Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Physician payment disclosure including S. 301, Physician Payments Sunshine Act of 2009; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Comparative effectiveness including S. 1213, Patient-Centered Outcomes Research Act of 2009; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Health care reform including H.R. 3200, America's Affordable Health Choices Act; S. , Affordable Health Choices Act; and S. , America's Healthy Future Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
2010 · first_quarter · Health Issues
Drug safety including H.R. 579, the Food and Drug Administration Globalization Act; Federal Prescription Issues Including Prescription Drug Labeling; Physician payment disclosure including S. 301, Physician Payments Sunshine Act of 2009; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Health care reform including H.R. 3200, America's Affordable Health Choices Act; S. , Affordable Health Choices Act; and S. , America's Healthy Future Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. and congressional oversight issues.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · first_quarter · Health Issues
Drug safety including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; H.R. 3590, Patient Protection and Affordable Care Act Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Physician payment disclosure legislation including S. 301, Physician Payments Sunshine Act of 2009; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Comparative effectiveness including S. 1213, Patient-Centered Outcomes Research Act of 2009; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Federal preemption for drugs and devices including H.R. 1346/S. 540, Medical Device Safety Act of 2009; Health care reform including H.R. 3200, America's Affordable Health Choices Act; Affordable Health Choices Act; and America's Healthy Future Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Prescription drug advertising; ESRD payments; and congressional oversight issues.
2009 · fourth_quarter · Consumer Issues/Safety/Products
Red Flags Rule; gift cards; H.R. 579 to amend the Federal Food, Drug, and Cosmetic Act to improve the safety of food, drugs, devices, and cosmetics in the global market communication of retail industry views; H.R. 875 to establish the Food Safety Administration within the Department of Health and Human Services to protect the public health by preventing food-borne illness communication of retail industry views; H.R. 1298 to amend the Federal Food, Drug and Cosmetic Act with respect to the importation of prescription drugs communication of retail industry views; Implementation of the Consumer Product Safety Improvement Act - concerns with the implementation of specific sections of the CPSIA including retroactivity, general conformity certificates, tracking labels and component testing; H.R. 1398/S. 558, Labeling Education and Nutrition Act, provisions requiring chain restaurants to provide nutritional information on menus and menu boards, provisions on premption, liability protection, and nutrition disclosure; RFID technology - privacy issues; H.R.2749, to amend the Federal Food, Drug, and Cosmetic Act to improve the safety of food in the global market, and for other purposes, provisions relating to increased penalties, reporting requirements and traceability requirements; Endorsement and support of S. 510, to amend the Federal Food, Drug, and Cosmetic Act with respect to food safety -- communication to Congress and Administrative agencies of retail and chain restaurant industry views.
Client expense: $460,000 · Firm income: Not reported
2009 · fourth_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S.1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act; Physician payment disclosure including S. 301, Physician Payment Sunshine Act of 2009; Comparative effectivess including H.R. 1, the American Recovery and Reinvestment Act; S. 1213, Patient-Centered Outcomes Research Act of 2009; Health information technology including H.R. 1, the American Recovery and Reinvestment Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; Health care reform; including H.R. 3200, America's Affordable Health Choices Act; S.___, Affordable Health Choices Act; and S.___ , America's Healthy Future Act; H.R. 3962, Affordable Health Care for America Act; and H.R. 3590, Patient Protection and Affordable Care Act; Prescription drug advertising; and Federal preemption for prescription drugs.
Client expense: Not reported · Firm income: $50,000
2009 · fourth_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act; Physician payment disclosure including S. 301, Physician Payments Sunshine Act of 2009; Comparative effectiveness including H.R. 1, the American Recovery and Reinvestment Act; S. 1213, Patient-Centered Outcomes Research Act of 2009; Health information technology including H.R. 1, the American Recovery and Reinvestment Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements indlucing S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; Health care reform including Affordable Health Choices Act, H.R. 3200, America's Affordable Health Choices Act, America's Healthy Future Act; H.R. 3962, Affordable Health Care for America Act; and H.R. 3590, Patient Protection and Affordable Care Act; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: Not reported · Firm income: $80,000
2009 · fourth_quarter · Consumer Issues/Safety/Products
Red Flags Rule; gift cards; H.R. 579 to amend the Federal Food, Drug, and Cosmetic Act to improve the safety of food, drugs, devices, and cosmetics in the global market communication of retail industry views; H.R. 875 to establish the Food Safety Administration within the Department of Health and Human Services to protect the public health by preventing food-borne illness communication of retail industry views; H.R. 1298 to amend the Federal Food, Drug and Cosmetic Act with respect to the importation of prescription drugs communication of retail industry views; Implementation of the Consumer Product Safety Improvement Act - concerns with the implementation of specific sections of the CPSIA including retroactivity, general conformity certificates, tracking labels and component testing; H.R. 1398/S. 558, Labeling Education and Nutrition Act, provisions requiring chain restaurants to provide nutritional information on menus and menu boards, provisions on premption, liability protection, and nutrition disclosure; RFID technology - privacy issues; H.R.2749, to amend the Federal Food, Drug, and Cosmetic Act to improve the safety of food in the global market, and for other purposes, provisions relating to increased penalties, reporting requirements and traceability requirements; Endorsement and support of S. 510, to amend the Federal Food, Drug, and Cosmetic Act with respect to food safety -- communication to Congress and Administrative agencies of retail and chain restaurant industry views.
Client expense: $460,000 · Firm income: Not reported
2009 · fourth_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act; Physician payment disclosure including S. 301, Physician Payments Sunshine Act of 2009; Comparative effectiveness including H.R. 1, the American Recovery and Reinvestment Act; S.1213, Patient-Centered Outcomes Research Act of 2009; Health information technology including H.R. 1, the American Recovery and Reinvestment Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; Health care reform including H.R. 3200, America's Affordable Health Choices Act; S___, Affordable Health Choices Act; and S. ___, America's Healthy Future Act; H.R. 3962, Affordable Health Care for America Act; and H.R. 3590, Patient Protection and Affordable Care Act; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: Not reported · Firm income: $60,000
2009 · fourth_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act; Physician payment disclosure including S. 301, Physician Payments Sunshine Act of 2009; Comparative effectiveness including H.R. 1, the American Recovery and Reinvestment Act; S. 1259, Preserving Access to Targeted, Individualized, and Effective New Treatments and Services Act of 2009; S. 1213, Patient-Centered Outcomes Research Act of 2009; Health information technology including H.R. 1, the American Recovery and Reinvestment Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; Health care reform including H.R. 3200, America's Affordable Health Choices Act; S.___, Affordable Health Choices Act; and S.___, America's Healthy Future Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; Prescription drug advertising; Federal preemption for prescription drugs; Legislation affecting telemedicine including H.R. 1, the American Recovery and Reinvestment Act; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: Not reported · Firm income: $100,000
2009 · fourth_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act; Physician payment disclosure including S. 301, Physician Payments Sunshine Act of 2009; Comparative effectiveness including H.R. 1, the American Recovery and Reinvestment Act; S. 1213, Patient-Centered Outcomes Research Act of 2009; Health information technology including H.R. 1, the American Recovery and Reinvestment Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; Health care reform including H.R. 3200, America's Affordable Health Choices Act; S. , Affordable Health Choices Act; and S. , America's Healthy Future Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: Not reported · Firm income: $50,000
2009 · fourth_quarter · Health Issues
Drug safety including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act; Physician payment disclosure legislation including S. 301, Physician Payments Sunshine Act of 2009; Comparative effectiveness including H.R. 1, the American Recovery and Reinvestment Act; S. 1213, Patient-Centered Outcomes Research Act of 2009; Health information technology including the American Recovery and Reinvestment Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; Federal preemption for drugs and devices including H.R. 1346/S. 540, Medical Device Safety Act of 2009; Health care reform including H.R. 3200, America's Affordable Health Choices Act; Affordable Health Choices Act; and America's Healthy Future Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; Prescription drug advertising; Bisphenol A including S. 593; and congressional oversight issues.
Client expense: Not reported · Firm income: $30,000
2009 · fourth_quarter · Health Issues
Drug safety including H.R. 579, the Food and Drug Administration Globalization Act; Federal Prescription Issues Including Prescription Drug Labeling; Physician payment disclosure including S. 301, Physician Payments Sunshine Act of 2009; Health care reform including H.R. 3200, America's Affordable Health Choices Act; Affordable Health Choices Act; and America's Healthy Future Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; and congressional oversight issues.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · third_quarter · Consumer Issues/Safety/Products
Red Flags Rule; gift cards; H.R. 579 to amend the Federal Food, Drug, and Cosmetic Act to improve the safety of food, drugs, devices, and cosmetics in the global market communication of retail industry views; H.R. 875 to establish the Food Safety Administration within the Department of Health and Human Services to protect the public health by preventing food-borne illness communication of retail industry views; H.R. 1298 to amend the Federal Food, Drug and Cosmetic Act with respect to the importation of prescription drugs communication of retail industry views; S. 510 to amend the Federal Food, Drug, and Cosmetic Act with respect to the safety of the food supply communication of retail industry views; Implementation of the Consumer Product Safety Improvement Act - concerns with the implementation of specific sections of the CPSIA including retroactivity, general conformity certificates, tracking labels and component testing; H.R. 1398/S. 558, Labeling Education and Nutrition Act, provisions requiring chain restaurants to provide nutritional information on menus and menu boards, provisions on premption, liability protection, and nutrition disclosure; RFID technology - privacy issues; H.R.2749, to amend the Federal Food, Drug, and Cosmetic Act to improve the safety of food in the global market, and for other purposes, provisions relating to increased penalties, reporting requirements and traceability requirements; letter to House of Representatives expressing concerns with H.R. 2749, the Food Safety Enhancement Act of 2009.
Client expense: $600,000 · Firm income: Not reported
Follow developments within the Administration relating to global health policies concerning U.S. government participation in WHO and UN health initiatives; international public health issues; U.S. sanctions policies; international vaccine issues; vaccine policy at the Pan American Health Organization; Childhood immunizations Dietary supplement issues Alzheimer's care Pediatric Studies and Trials Drug Safety/Clinical Trials Health care reform legislation FDA Pre-emption Follow-on biologics Drug importation and counterfeiting Drug advertising Comparative effectiveness Physician payment disclosure Chronic care out of pocket costs Vaccine Program H.R. 1427 - Access to Life-Saving Medicine Act H.R. 1548 - The Pathway for Biosimilars Act Legislative and regulatory issues related to hormone replacement therapies International public health issues International vaccine issues H.R. 1/S350 - The American Recovery and Reinvestment Act of 2009 H.R. 579 - The Food and Drug Administration Globalization Act S. 525/H.R. 1298 - The Pharmaceutical Market Access and Drug Safety Act of 2009 S. 301 - Physican Payments Sunshine Act of 2009 H.R. 573 - Authorized Generics S. 501 - Fair Prescription Drug Competition Act S. 369 - Preserve Access to Affordable Generics Act H.R. 1706 - Protecting consumer Access to Generic Drugs Act S.357 - Sunshine in Litigation Act of 2009 H.R. 3200 - American's Affordable Health Choices Act of 2009 S.1679 Affordable Health Choices Act S.1213 - Patient Centered Outcomes Research Act of 2009
Client expense: $681,738 · Firm income: Not reported
2009 · third_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S.1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act; Physician payment disclosure including S. 301, Physician Payment Sunshine Act of 2009; Comparative effectivess including H.R. 1, the American Recovery and Reinvestment Act; S. 1213, Patient-Centered Outcomes Research Act of 2009; Health information technology including H.R. 1, the American Recovery and Reinvestment Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; Health care reform; including H.R. 3200, America's Affordable Health Choices Act; S.___, Affordable Health Choices Act; and S.___ , America's Healthy Future Act; Prescription drug advertising; and Federal preemption for prescription drugs.
Client expense: Not reported · Firm income: $50,000
2009 · third_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act; Physician payment disclosure including S. 301, Physician Payments Sunshine Act of 2009; Comparative effectiveness including H.R. 1, the American Recovery and Reinvestment Act; S.1213, Patient-Centered Outcomes Research Act of 2009; Health information technology including H.R. 1, the American Recovery and Reinvestment Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; Health care reform including H.R. 3200, America's Affordable Health Choices Act; S___, Affordable Health Choices Act; and S. ___, America's Healthy Future Act; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: Not reported · Firm income: $80,000
2009 · third_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act; Physician payment disclosure including S. 301, Physician Payments Sunshine Act of 2009; Comparative effectiveness including H.R. 1, the American Recovery and Reinvestment Act; S. 1259, Preserving Access to Targeted, Individualized, and Effective New Treatments and Services Act of 2009; S. 1213, Patient-Centered Outcomes Research Act of 2009; Health information technology including H.R. 1, the American Recovery and Reinvestment Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; Health care reform including H.R. 3200, America's Affordable Health Choices Act; S.___, Affordable Health Choices Act; and S.___, America's Healthy Future Act; Prescription drug advertising; Federal preemption for prescription drugs; Legislation affecting telemedicine including H.R. 1, the American Recovery and Reinvestment Act; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: Not reported · Firm income: $20,000
2009 · third_quarter · Health Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act; Physician payment disclosure including S. 301, Physician Payments Sunshine Act of 2009; Comparative effectiveness including H.R. 1, the American Recovery and Reinvestment Act; S. 1213, Patient-Centered Outcomes Research Act of 2009; Health information technology including H.R. 1, the American Recovery and Reinvestment Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; Health care reform including H.R. 3200, America's Affordable Health Choices Act; S.___, Affordable Health Choices Act; and S.___, America's Healthy Future Act; Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: Not reported · Firm income: $50,000
2009 · third_quarter · Health Issues
Drug safety including H.R. 579, the Food and Drug Administration Globalization Act; Federal Prescription Issues Including Prescription Drug Labeling; Physician payment disclosure including S. 301, Physician Payments Sunshine Act of 2009; Health care reform including H.R. 3200, America's Affordable Health Choices Act; Affordable Health Choices Act; and America's Healthy Future Act; and congressional oversight issues.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · third_quarter · Health Issues
Drug safety including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act; Physician payment disclosure legislation including S. 301, Physician Payments Sunshine Act of 2009; Comparative effectiveness including H.R. 1, the American Recovery and Reinvestment Act; S. 1213, Patient-Centered Outcomes Research Act of 2009; Health information technology including the American Recovery and Reinvestment Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; Federal preemption for drugs and devices including H.R. 1346/S. 540, Medical Device Safety Act of 2009; Health care reform including H.R. 3200, America's Affordable Health Choices Act; Affordable Health Choices Act; and America's Healthy Future Act; Prescription drug advertising; Bisphenol A including S. 593; and congressional oversight issues.
Client expense: Not reported · Firm income: $30,000
| Democratic |
| MD |
| David Loebsack | Democratic | IA |
| David Wu | Democratic | OR |
| Earl Blumenauer | Democratic | OR |
| Eric Massa | Democratic | NY |
| Frank Pallone, Jr. | Democratic | NJ |
| Gerald E. Connolly | Democratic | VA |
| Gregory W. Meeks | Democratic | NY |
| Howard L. Berman | Democratic | CA |
| James P. McGovern | Democratic | MA |
| Janice D. Schakowsky | Democratic | IL |
| Jared Polis | Democratic | CO |
| Jay Inslee | Democratic | WA |
| Jerry McNerney | Democratic | CA |
| Joe Courtney | Democratic | CT |
| John Hall | Democratic | NY |
| Lois Capps | Democratic | CA |
| Madeleine Z. Bordallo | Democratic | GU |
| Maurice D. Hinchey | Democratic | NY |
| Mazie K. Hirono | Democratic | HI |
| Michael H. Michaud | Democratic | ME |
| Michael M. Honda | Democratic | CA |
| Paul Tonko | Democratic | NY |
| Raúl M. Grijalva | Democratic | AZ |
| Robert Wexler | Democratic | FL |
| Russ Carnahan | Democratic | MO |
| Steve Cohen | Democratic | TN |
| Vernon Ehlers | Republican | MI |
| Yvette D. Clarke | Democratic | NY |
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), Federal Reserve System, Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Internal Revenue Service (IRS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Security Council (NSC), Office of the Comptroller of the Currency (OCC), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Customs & Border Protection, U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR), White House Office
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), Federal Reserve System, Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Internal Revenue Service (IRS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Security Council (NSC), Office of the Comptroller of the Currency (OCC), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Customs & Border Protection, U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR), White House Office
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), Federal Reserve System, Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Internal Revenue Service (IRS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Security Council (NSC), Office of the Comptroller of the Currency (OCC), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Customs & Border Protection, U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR), White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Security Agency (NSA), Natl Security Council (NSC), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE